Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study

• Published in: Arthritis & rheumatology (Hoboken, N.J.) Vol. 66; no. 2; pp. 379 - 389
• Main Authors: Furie, Richard, Nicholls, Kathy, Cheng, Tien‐Tsai, Houssiau, Frederic, Burgos‐Vargas, Ruben, Chen, Shun‐Le, Hillson, Jan L., Meadows‐Shropshire, Stephanie, Kinaszczuk, Michael, Merrill, Joan T.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2014
• Subjects: Abatacept; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunoconjugates - therapeutic use; Immunosuppressive Agents - therapeutic use; Internationality; Longitudinal Studies; Lupus; Lupus Nephritis - drug therapy; Male; Severity of Illness Index; Treatment Outcome

Objective To compare the efficacy and safety of intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of active class III or IV lupus nephritis, when used on a background of mycophenolate mofetil and glucocorticoids. Methods This was a 12‐month, ran...